Table 2.
Patients’ experiences and stress levels regarding medication and odds of concern in women in comparison to men
|
Variables n (n = Yes response out
of total response) (%) |
Gender [n (%)]
|
Level of stress
[n (%)] |
P | OR (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Female | Male | Very high | High | Medium | Low | Very low | |||
| Concern for medicine unavailability over the last year 873/1017 (85.8) |
705 (87.0) | 168 (81.2) | 340 (40.2) | 220 (26.0) | 197 (23.3) | 51 (6.0) | 38 (4.5) | 0.03* | 1.55 (1.04-2.33)* |
| Concern for medicine unavailability in the future as sanctions continue 941/1005 (93.6) |
755 (94.4) | 186 (90.7) | 527 (56.0) | 243 (25.9) | 112 (11.9) | 37 (3.9) | 22 (2.3) | 0.05 | 1.71 (0.97-3.00) |
| Concern for supply and purchase of foreign medicine over the last year 837/973 (86.0) |
671 (86.7) | 166 (83.4) | 463 (55.3) | 205 (24.5) | 119 (14.2) | 24 (2.9) | 26 (3.1) | 0.23 | 1.29 (0.84-1.96) |
| Concern for supply and purchase of foreign medicine in the future as sanctions continue 858/962 (89.2) |
685 (89.7) | 173 (87.4) | 521 (60.7) | 188 (21.9) | 105 (12.2) | 23 (2.7) | 21 (2.4) | 0.35 | 1.25 (0.77-2.02) |
| Concern for replacing internationally branded medicines with Iranian branded medicines because of price increase in the future as sanctions continue 684/939 (72.8) |
548 (73.7) | 136 (69.7) | 359 (52.5) | 185 (27.0) | 81 (11.8) | 32 (4.7) | 27 (3.9) | 0.27 | 1.21 (0. 85-1.71) |
| Concern for replacing expensive drugs with cheaper alternatives due to financial problems in the future as sanctions continue 671/954 (70.3) |
527 (69.6) | 144 (73.1) | 322 (48.1) | 196 (29.3) | 90 (13.4) | 35 (5.2) | 27 (4.0) | 0.34 | 0.84 (0.59-1.19) |
| Concerns about the effectiveness of Iranian drugs in comparison with foreign ones 795/970 (82.0) |
637 (82.3) | 158 (80.6) | 401 (50.8) | 209 (26.5) | 127 (16.1) | 30 (3.8) | 23 (2.9) | 0.58 | 1.11 (0.75-1.66) |
| Unwillingness to continue treatment due to increased economic burden of the disease 427/1031 (41.4) |
315 (38.4) | 112 (53.3) | 215 (50.6) | 89 (20.9) | 53 (12.5) | 31 (7.3) | 37 (8.7) | < 0.01 | 0.54 (0.40-0.73)* |
| Unwillingness to continue treatment due to increased mental burden 440/1026 (42.9) |
338 (32.9) | 102 (49.0) | 212 (48.4) | 106 (24.2) | 47 (10.7) | 33 (7.5) | 40 (9.1) | 0.04 | 0.73 (0.53-0.93)* |
OR: Odds ratio; CI: Confidence interval
*
Significant results compared to other odds ratios and 95% confidence intervals (CI)